Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function
Research output: Contribution to journal › Review › Research › peer-review
Standard
Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function. / Kickinger, Stefanie; Hellsberg, Eva; Frølund, Bente; Schousboe, Arne; Ecker, Gerhard F; Wellendorph, Petrine.
In: Neuropharmacology, Vol. 161, 107644, 2019.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function
AU - Kickinger, Stefanie
AU - Hellsberg, Eva
AU - Frølund, Bente
AU - Schousboe, Arne
AU - Ecker, Gerhard F
AU - Wellendorph, Petrine
N1 - Copyright © 2019. Published by Elsevier Ltd.
PY - 2019
Y1 - 2019
N2 - ɣ-aminobutyric-acid (GABA) functions as the principal inhibitory neurotransmitter in the central nervous system. Imbalances in GABAergic neurotransmission are involved in the pathophysiology of various neurological diseases such as epilepsy, Alzheimer's disease and stroke. GABA transporters (GATs) facilitate the termination of GABAergic signaling by transporting GABA together with sodium and chloride from the synaptic cleft into presynaptic neurons and surrounding glial cells. Four different GATs have been identified that all belong to the solute carrier 6 (SLC6) transporter family: GAT1-3 (SLC6A1, SLC6A13, SLC6A11) and betaine/GABA transporter 1 (BGT1, SLC6A12). BGT1 has emerged as an interesting target for treating epilepsy due to animal studies that reported anticonvulsant effects for the GAT1/BGT1 selective inhibitor EF1502 and the BGT1 selective inhibitor RPC-425. However, the precise involvement of BGT1 in epilepsy remains elusive because of its controversial expression levels in the brain and the lack of highly selective and potent tool compounds. This review gathers the current structural and functional knowledge on BGT1 with emphasis on brain relevance, discusses all available compounds, and tries to shed light on the molecular determinants driving BGT1 selectivity.
AB - ɣ-aminobutyric-acid (GABA) functions as the principal inhibitory neurotransmitter in the central nervous system. Imbalances in GABAergic neurotransmission are involved in the pathophysiology of various neurological diseases such as epilepsy, Alzheimer's disease and stroke. GABA transporters (GATs) facilitate the termination of GABAergic signaling by transporting GABA together with sodium and chloride from the synaptic cleft into presynaptic neurons and surrounding glial cells. Four different GATs have been identified that all belong to the solute carrier 6 (SLC6) transporter family: GAT1-3 (SLC6A1, SLC6A13, SLC6A11) and betaine/GABA transporter 1 (BGT1, SLC6A12). BGT1 has emerged as an interesting target for treating epilepsy due to animal studies that reported anticonvulsant effects for the GAT1/BGT1 selective inhibitor EF1502 and the BGT1 selective inhibitor RPC-425. However, the precise involvement of BGT1 in epilepsy remains elusive because of its controversial expression levels in the brain and the lack of highly selective and potent tool compounds. This review gathers the current structural and functional knowledge on BGT1 with emphasis on brain relevance, discusses all available compounds, and tries to shed light on the molecular determinants driving BGT1 selectivity.
U2 - 10.1016/j.neuropharm.2019.05.021
DO - 10.1016/j.neuropharm.2019.05.021
M3 - Review
C2 - 31108110
VL - 161
JO - Neuropharmacology
JF - Neuropharmacology
SN - 0028-3908
M1 - 107644
ER -
ID: 225121505